- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07691762
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma.
Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Junqin Yang
- Telefonnummer: +86-0518-82342973
- E-post: junqin.yang@hengrui.com
Studera Kontakt Backup
- Namn: Huan Wang
- Telefonnummer: +86-0518-82342973
- E-post: huan.wang.hw396@hengrui.com
Studieorter
-
-
Jiangsu
-
Nanjing, Jiangsu, Kina, 210009
- Zhongda Hospital Southeast University
-
Huvudutredare:
- Gaojun Teng
-
Kontakt:
- Gaojun Teng
- Telefonnummer: +86-025-83272084
- E-post: gjteng@seu.edu.cn
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200032
- Zhongshan Hospital, Fudan University
-
Huvudutredare:
- Jia Fan
-
Kontakt:
- Jia Fan
- Telefonnummer: +86-021-64041990
- E-post: fan.jia@zs-hospital.sh.cn
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Age 18-75 years old, male or female;
- Diagnosis confirmed HCC by pathologically or clinically;
- At least one measurable lesion;
- Child-Pugh liver function grade A;
- ECOG-PS score: 0 or 1;
- Eligible for TACE treatment as assessed by the investigator;
- Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
- Consent to contraception.
Exclusion Criteria:
- Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
- Participants with any active, known or suspected autoimmune disorder;
- Participants with hypertension which cannot be well controlled by antihypertensives;
- Uncontrolled cardiac diseases or symptoms;
- Participants with hepatic encephalopathy;
- Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment;
- History of gastrointestinal perforation and/or fistula;
- Participants with other potential factors that may affect the study results.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Treatment group A
SHR-8068 + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
|
Aktiv komparator: Treatment group B
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab Placebo + Bevacizumab Placebo, intravenous infusion, Transarterial Chemoembolization(TACE) |
|
Experimentell: Treatment group C
SHR-8068 Placebo + Adebrelimab + Bevacizumab + Transarterial Chemoembolization (TACE) |
SHR-8068 Placebo + Adebrelimab + Bevacizumab, intravenous infusion, Transarterial Chemoembolization (TACE) |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Progression-free survival (PFS) assessed by investigator
Tidsram: Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Adverse events (AEs)
Tidsram: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Serious adverse events (SAEs)
Tidsram: Until study completion, assessed up to approximately 3 years.
|
Until study completion, assessed up to approximately 3 years.
|
|
Progression-free survival (PFS) assessed by Blinded Independent Review Committee (BIRC)
Tidsram: Until progression, assessed up to approximately 2 years.
|
Until progression, assessed up to approximately 2 years.
|
|
Overall survival (OS)
Tidsram: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Objective response rate (ORR)
Tidsram: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Disease control rate (DCR)
Tidsram: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Duration of objective tumor response (DoR)
Tidsram: Until study completion, assessed up to approximately 2 years.
|
Until study completion, assessed up to approximately 2 years.
|
|
Pharmacokinetics parameters of SHR-8068 and Adebrelimab: serum concentration
Tidsram: Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
|
Immunogenicity indicators of SHR-8068 and Adebrelimab: drug resistant antibody (ADA) and neutralizing antibody (NAb)
Tidsram: Approximately 90 days post-last dose.
|
Approximately 90 days post-last dose.
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Beräknad)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Neoplasmer efter plats
- Neoplasmer
- Neoplasmer efter histologisk typ
- Neoplasmer i matsmältningssystemet
- Matsmältningssystemets sjukdomar
- Leversjukdomar
- Neoplasmer, körtel och epitel
- Adenocarcinom
- Neoplasmer i levern
- Carcinom
- Karcinom, hepatocellulärt
- Aminosyror, peptider och proteiner
- Proteiner
- Antikroppar, monoklonal, humaniserad
- Antikroppar, monoklonal
- Antikroppar
- Immunglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Bevacizumab
Andra studie-ID-nummer
- SHR-8068-305
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .